184.44 0.00 (0.00%)
After hours: 6:07PM EDT
|Bid||184.01 x 1100|
|Ask||184.43 x 1100|
|Day's Range||183.28 - 186.78|
|52 Week Range||166.30 - 210.19|
|Beta (3Y Monthly)||0.91|
|PE Ratio (TTM)||14.71|
|Earnings Date||Jul 30, 2019|
|Forward Dividend & Yield||5.80 (3.14%)|
|1y Target Est||205.55|
SAN FRANCISCO, June 25, 2019 /PRNewswire/ -- Amgen (AMGN) and MBC BioLabs (formerly QB3@953) today announced that Regencor and Nitrome Biosciences have each been awarded an Amgen Golden Ticket to MBC BioLabs. The companies receive priority admission or renewal for one year of lab bench space and access to core facilities at the MBC BioLabs life sciences incubator, as well as connections to Amgen's scientific and business leaders to help advance their scientific programs. Amgen has been sponsoring MBC BioLabs since 2016 to assist high-potential and innovative early-stage life science and biotech companies in their efforts to accelerate the development of new therapies to improve human health.
Allergan's (AGN) Botox gets FDA approval for the 10th therapeutic indication, upper limb spasticity in pediatric patients, in the age group of 2 to 17 years.
Health-care reform is coming, UBS analysts say, and it could have severe consequences for health companies.
THOUSAND OAKS, Calif. and SEATTLE, June 19, 2019 /PRNewswire/ -- Amgen (AMGN) and the University of Washington's Institute for Protein Design (IPD), which is revolutionizing its field of science by creating custom-designed proteins from scratch to improve human health, today announced a broad collaboration that will cover multiple projects with a goal of testing new technologies and creating protein-building approaches that can be broadly applied to the search for new medicines. Under the terms of the agreement, Amgen has provided initial funding for three sponsored research projects that will seek to apply IPD's de novo design technique to increase the versatility of traditional protein-based medicines. This will include optimizing Amgen's repertoire of BiTE® (bispecific T cell enager) antibodies, with the goal of expanding the types of tumors that can be targeted with these molecules.
Do you want to find the next Apple (NASDAQ:AAPL) or Amazon (NASDAQ:AMZN)? My advice is that you should set your sights lower, not higher and put some cash to work in three down, but not out heavyweight biotech stocks for the next big thing in investing. Let me explain.It has been a good week so far for the broader markets. The Nasdaq Composite, S&P 500 and Dow Jones Industrial Average have broken out of short bases barely discernible on the weekly chart and back within spitting distance of their respective all-time-highs following May's abrupt correction. It has been a nice period for biotech stocks as well.The Vaneck Vectors Biotech ETF (NYSEARCA:BBH) is up nearly 3.50% through Tuesday's close compared to gains of roughly 1% to 2% for the broader averages. But as any investor with a passing interest in the markets knows, the outperformance in biotech stocks has been anything but a recurring theme these past couple years.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 7 Hot Stocks to Buy for a Seemingly Sleepy Summer The good news is markets are cyclical. Even legendary investments such as AMZN or the sacrosanct AAPL stock have been known to correct for periods lasting not weeks, but months and even years. With that in mind, it's time to consider adding these three large-cap biotech stocks into your portfolio. Amgen (AMGN) Click to EnlargeAmgen (NASDAQ:AMGN) is a biotech heavyweight that also happens to be the sector's largest capitalization outfit with a valuation of about $110 billion.Following a recent sales and earnings beat, this reasonably-priced biotech giant, which pays investors nearly 3.5% in quarterly dividends, has now put together a bottom on the monthly price chart.Specifically, AMGN stock has formed a confirmed pivot low, which reaffirms its longstanding uptrend after a correction of several months. And with plenty of lateral, angular and Fibonacci price supports, as well as an oversold crossover signal to confirm the bottom, this biotech stock is a buy today.The TradeBuy AMGN stock at current prices. Set a stop-loss beneath support below $160, but expect shares to hit new highs in 2019's second half. Gilead Sciences (GILD) Click to EnlargeIt has been a rough few years for Gilead Sciences (NASDAQ:GILD), one the sector's largest names, but things are looking up for GILD stock lately.A recent earnings report that reiterated the company's full-year guidance and offered a modest year-over-year uptick in sales and profits looks promising for Gilead shares, which have been absolutely pummeled over the last four years.Technically, shares are trading slightly above multiple inside candlesticks following a double bottom pattern of about one and a half years. With the formation finding support off the 50% retracement level and a supportive-looking stochastics set-up signaling better months and years ahead, GILD stock looks good to buy right now. * 10 'Buy-and-Hold' Stocks to Own Forever The TradeBuy GILD stock at current levels with an initial stop-loss below $59. On the upside, $85 - $90 looks like a good area for profit-taking while allowing this down-and-out value stock some room to run. Biogen (BIIB) Click to EnlargeMuch like GILD stock, shares of sector heavyweight Biogen (NASDAQ:BIIB) have been under extreme technical duress the past few years.Most recently, the pain in BIIB stock came after the company's announcement that it was axing a drug to treat Alzheimer's following poor results. The suffering came despite the fact that BIIB posted stronger-than-forecast results in late April.On the price chart, this biotech stock's technical beating since 2015 has resulted in a possible four-year long double-bottom pattern that's finding support in-between the 50% and 62% retracement levels. Coupled with an oversold stochastics that is a hair's breadth away from signaling a bullish crossover, confirmation of the pivot low looks imminent.The TradeBuy BIIB stock above May's candle high of $238.17 to confirm the pattern bottom. I'd suggest an initial stop beneath $214 and to take partial profits in-between $300 - $310.Disclosure: Investment accounts under Christopher Tyler's management currently do not own positions in any of the securities mentioned in this article. The information offered is based upon Christopher Tyler's observations and strictly intended for educational purposes only; the use of which is the responsibility of the individual. For additional market insights and related musings, follow Chris on Twitter @Options_CAT and StockTwits. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 Value Stocks to Buy for the Second Half * 7 Hot Stocks to Buy for a Seemingly Sleepy Summer * 6 Chip Stocks Staring At Big Headwinds in 2019 Compare Brokers The post 3 Large-Cap Biotech Stocks to Buy for Massive Gains appeared first on InvestorPlace.
The Zacks Analyst Blog Highlights: Broadcom, Amgen, NVIDIA, Bristol-Myers and Restaurant Brands
Merck (MRK) receives FDA approval for Keytruda's label expansion in small cell lung cancer indication, marking the drug's first approval in this indication.
There has been a flurry of M&A deal announcements this year in the drug industry. Here we discuss three big drug/biotech companies, which may make the next M&A move.
Roche's (RHHBY) oncology portfolio gets a boost with the approval of Rozlytrek for neurotrophic tyrosine receptor kinase fusion-positive, advanced recurrent solid tumors.
Amgen Inc NASDAQ/NGS:AMGNView full report here! Summary * Perception of the company's creditworthiness is neutral * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for AMGN with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting AMGN. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold AMGN had net inflows of $3.31 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swap | NeutralThe current level displays a neutral indicator. AMGN credit default swap spreads are decreasing, indicating some improvement in the market's perception of the company's credit worthiness. Additionally, they are within the middle of the range set over the last three years.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
When you prepare an enjoyable "investing trip" and are looking for great stocks, it's beneficial to use a check list to study the chart action.
Shares of gene-therapy companies shot up on Monday after Pfizer Inc. announced it would acquire cancer drug maker Array BioPharma Inc. in a deal worth up to $11.4 billion.
Phase 2 Single-Arm BLAST Study Shows Median Overall Survival of 36.5 Months in Patients With Minimal Residual Disease-Positive Acute Lymphoblastic Leukemia More Than Half of Patients who Achieved an MRD-Negative ...
U.S. drugmakers filed a lawsuit on Friday challenging a new government regulation that would require them to disclose the list price of prescription drugs in direct-to-consumer television advertisements. The lawsuit was jointly filed by Amgen Inc, Merck & Co, Eli Lilly and Co and the Association Of National Advertisers in the U.S. district court for the district of Columbia. The new regulation, which was finalized on May 8 by the U.S. Department of Health and Human Services (HHS) and set to take effect in July, is part of the government's efforts to bring down the cost of prescription medicines for U.S. consumers.
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs June 12) • Abbott Laboratories (NYSE: ABT ) • Avedro ...
that forces them to include drug prices in their TV advertisements hinders their free speech. The companies claim the rule exceeds the authority of the federal department that issued it, the health and human services department, and violates First Amendment speech protections.